CAR-T therapy, breakthrough of the year, agenda now released for Europe congress

- Tweet0
- 0
- Pin It 0
- 0
- Subscribe to RSS
Subscribe

Subject: CAR-T therapy, breakthrough of the year, agenda now released for Europe congress

Agenda released for CAR-T Congress Europe 2019

Dear colleague,

CAR-T cell immunotherapy is at the forefront of innovative cancer therapeutics, with leaps in progress over the past year. Following the recent EU approval for CAR-T, the heat is on to tackle solid tumours, improve safety and most importantly improve patient access to these life-saving therapies.

Now in it’s third year, the CAR-T Congress Europe in London on 30 - 31 January 2019 brings together stakeholders across industry and academia to address the critical challenges head-on and stimulate discussion to identify the unmet needs.

Novartis & Kite share insights on how to accelerate approval in the European market.
John Maher at King’s College shares unpublished research on how to overcome the tumour microenvironment.
Strategise and understand toxicity, with Novartis how they plan to improve safety.
Improve manufacturing with automation to lower cost & increase the scope of the therapies from innovators such as Torque Therapeutics.
Hear from Cellectis, Celyad & Servier on their approaches to off-the-shelf products.
Address critical challenges in CAR-T with leading biotechs including, Gadeta & bluebirdbio.

Subscribe

Subject: CAR-T therapy, breakthrough of the year, agenda now released for Europe congress